{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:13:28Z","timestamp":1767831208965,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","award":["F.No. T.11011\/02\/2017-HR\/3100291"],"award-info":[{"award-number":["F.No. T.11011\/02\/2017-HR\/3100291"]}],"id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40258-024-00877-1","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T03:02:49Z","timestamp":1709780569000},"page":"569-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India"],"prefix":"10.1007","volume":"22","author":[{"given":"Jyoti","family":"Dixit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath Nookala","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha Sarathi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal Chandra","family":"Kataki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7719-6986","authenticated-orcid":false,"given":"Shankar","family":"Prinja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"K Palumbo","year":"2011","unstructured":"Palumbo K. Anderson, multiple myeloma. N Engl J Med. 2011;364:1046\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011442.","journal-title":"N Engl J Med"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3324\/haematol.2014.110296","volume":"99","author":"S Zweegman","year":"2014","unstructured":"Zweegman S, Palumbo A, Bringhen S, Sonneveld P. Age and aging in blood disorders: multiple myeloma. Haematologica. 2014;99:1133\u20137. https:\/\/doi.org\/10.3324\/haematol.2014.110296.","journal-title":"Haematologica"},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385:2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1.","journal-title":"Lancet"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","volume":"59","author":"K Bora","year":"2019","unstructured":"Bora K. Cancer Epidemiol. 2019;59:215-220 219.","journal-title":"Cancer Epidemiol"},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386. https:\/\/doi.org\/10.1002\/ijc.29210.","journal-title":"Int J Cancer"},{"key":"877_CR6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492n.d.;0","author":"F Bray","year":"2019","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2019. https:\/\/doi.org\/10.3322\/caac.21492n.d.;0.","journal-title":"CA Cancer J Clin"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.6004\/jnccn.2009.0062","volume":"7","author":"JP Laubach","year":"2009","unstructured":"Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009;7:947\u201360.","journal-title":"J Natl Compr Canc Netw"},{"key":"877_CR9","doi-asserted-by":"crossref","unstructured":"Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi133\u2013vi137.","DOI":"10.1093\/annonc\/mdt297"},{"issue":"6","key":"877_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587\u2013600.","journal-title":"J Clin Oncol"},{"key":"877_CR11","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115\u20131123.","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"877_CR12","doi-asserted-by":"publisher","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","DOI":"10.1056\/NEJMoa1606038"},{"key":"877_CR13","doi-asserted-by":"crossref","unstructured":"Durie BG, Hoering A, Abidi MH, et al.\u00a0Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.\u00a0Lancet. 2017;389:519\u2013527.","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"877_CR14","doi-asserted-by":"crossref","unstructured":"Moreau P, Hulin C, Macro M, et al.\u00a0VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.\u00a0Blood. 2016;127:2569\u20132574.","DOI":"10.1182\/blood-2016-01-693580"},{"key":"877_CR15","doi-asserted-by":"publisher","unstructured":"Fu S, et al. Cost effectiveness of transplant, conventional chemotherapy, and novel agents in multiple myeloma: a systematic review. PharmacoEconomics. https:\/\/doi.org\/10.1007\/s40273-019-00828-y.","DOI":"10.1007\/s40273-019-00828-y"},{"key":"877_CR16","doi-asserted-by":"crossref","unstructured":"Garrison LP Jr, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, et al. The cost-efectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013;18(1):27\u201336.","DOI":"10.1634\/theoncologist.2011-0380"},{"issue":"4","key":"877_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000364880","volume":"87","author":"MY Kim","year":"2014","unstructured":"Kim MY, Sposto R, Swaika A, Asano H, Alamgir A, ChananKhan A, et al. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology. 2014;87(4):224\u201331.","journal-title":"Oncology"},{"key":"877_CR18","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, et al. Cost-efectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016;19(3):243\u201358.","DOI":"10.3111\/13696998.2015.1115407"},{"key":"877_CR19","doi-asserted-by":"crossref","unstructured":"Chen Y, Lairson DR, Chan W, Huo J, Du XL. Cost-efectiveness of novel agents in medicare patients with multiple myeloma: fndings from a U.S. payer\u2019s perspective. J Manag Care Spec Pharm. 2017;23(8):831\u201343.","DOI":"10.18553\/jmcp.2017.23.8.831"},{"issue":"1","key":"877_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12288-017-0776-1","volume":"33","author":"SK Prinja","year":"2017","unstructured":"Prinja SK, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, et al. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus. 2017;33(1):31\u201340.","journal-title":"Indian J Hematol Blood Transfus."},{"issue":"15","key":"877_CR21","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"P Greipp","year":"2005","unstructured":"Greipp P, Miguel J, Durie B, Crowley J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"key":"877_CR22","doi-asserted-by":"crossref","unstructured":"Prinja S, Dixit J, Gupta N, Mehra N, Singh A, Krishnamurthy MN, et al. Development of National Cancer Database for Cost and Quality of Life (CaDCQoL) in India: a protocol. BMJ Open [Internet]. 2021;11(7):e048513. https:\/\/bmjopen.bmj.com\/content\/11\/7\/e048513. Accessed 30 Nov 2023.","DOI":"10.1136\/bmjopen-2020-048513"},{"key":"877_CR23","unstructured":"Guidelines|Indian Council of Medical Research|Government of India [Internet]. [cited 2020 Jul 10]. http:\/\/14.143.90.243\/icmr\/guidelines. Accessed 30 Nov 2023."},{"key":"877_CR24","unstructured":"Health Technology Assessment in India (HTAIn)\u2014HTAIn Manual [Internet]. [cited 2020 Nov 21]. https:\/\/htain.icmr.org.in\/index.php\/documents\/publications\/htain-manual. Accessed 30 Nov 2023."},{"key":"877_CR25","unstructured":"Sharma D, Prinja S, Aggarwal AK, Rajsekar K, Bahuguna P. Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment. Lancet Reg Health Southeast Asia [Internet]. 2023. https:\/\/www.thelancet.com\/journals\/lansea\/article\/PIIS2772-3682(23)00101-4\/fulltext#secsectitle011. Accessed 30 Nov 2023."},{"issue":"2","key":"877_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ispor health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health."},{"key":"877_CR27","doi-asserted-by":"publisher","unstructured":"Kumar L, Gundu N, Kancharia H, Sahoo RK, Malik PS, Sharma A, Gupta R, Sharma O, Biswas A, Kumar R, Thulkar S, Mallick S; AIIMS Myeloma Group. Multiple myeloma-effect of induction therapy on transplant outcomes.\u00a0Clin Lymphoma Myeloma Leuk. 2021;21(2):80\u201390.e5. https:\/\/doi.org\/10.1016\/j.clml.2020.08.021. (Epub 2020 Sep 19).","DOI":"10.1016\/j.clml.2020.08.021"},{"issue":"6","key":"877_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743\u201354. https:\/\/doi.org\/10.1177\/0272989X12472398.","journal-title":"Med Decis Mak"},{"key":"877_CR29","unstructured":"Engauge Digitizer [Internet]. Markummitchell.github.io. 2022 [cited 16 June 2022]. http:\/\/markummitchell.github.io\/engauge-digitizer\/. Accessed 30 Nov 2023."},{"key":"877_CR30","unstructured":"Kumar et al. 2022. Effect of Induction Therapy on Transplant and Non-transplant Outcomes among multiple myeloma patients in India. [Unpublished data]."},{"issue":"4","key":"877_CR31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","volume":"5","author":"PM Voorhees","year":"2021","unstructured":"Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021;5(4):1092\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2020003642.","journal-title":"Blood Adv"},{"key":"877_CR32","unstructured":"Registrar General & Census Commissioner of India. SRS BULLETIN 2014 [Internet]. [cited 2020 Nov 8]. https:\/\/censusindia.gov.in\/vital_statistics\/SRS_Bulletins\/SRS%20Bulletin%20-Sepetember%202014.pdf. Accessed 30 Nov 2023."},{"key":"877_CR33","doi-asserted-by":"publisher","unstructured":"Fox-Rushby J, Cairns J. Economic evaluation [Internet]. McGraw-Hill Education; 2005 [cited 2020 Oct 8]. 1. https:\/\/doi.org\/10.1036\/9780335225064. Accessed 30 Nov 2023.","DOI":"10.1036\/9780335225064"},{"issue":"7","key":"877_CR34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","volume":"25","author":"G Jyani","year":"2022","unstructured":"Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, Goyal A, Purba FD, Finch AP, Rajsekar K, Raman S, Stolk E, Kaur M. Development of an EQ-5D value set for india using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set. Value Health. 2022;25(7):1218\u201326. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1370.","journal-title":"Value Health."},{"key":"877_CR35","unstructured":"Health Benefit Package-2.0|Official Website Ayushman Bharat Pradhan Mantri Jan Arogya Yojana|National Health Authority [Internet]. [cited 2021 Jun 16]. https:\/\/pmjay.gov.in\/node\/1128. Accessed 30 Nov 2023."},{"key":"877_CR36","unstructured":"CGHS rate list - CGHS: Central Government Health Scheme [Internet]. [cited 2021 Jun 16]. https:\/\/cghs.gov.in\/index1.php?lang=1&level=3&sublinkid=5948&lid=3881. Accessed 30 Nov 2023."},{"key":"877_CR37","unstructured":"US Dollar to Indian Rupee Spot Exchange Rates for 2021 [Internet]. [cited 2021 Jul 6]. https:\/\/www.exchangerates.org.uk\/USD-INR-spot-exchange-rates-history-2021.html. Accessed 30 Nov 2023."},{"issue":"2","key":"877_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0272989X8500500205","volume":"5","author":"P Doubilet","year":"1985","unstructured":"Doubilet P, Begg CB, Weinstein MC, Braun P, Mcneil BJ. Probabilistic sensitivity analysis using monte carlo simulation: a practical approach. Med Decis Mak [Internet]. 1985;5(2):157\u201377. https:\/\/doi.org\/10.1177\/0272989X8500500205.","journal-title":"Med Decis Mak [Internet]."},{"key":"877_CR39","unstructured":"GDP per capita (current US$) - India|Data [Internet]. [cited 2020 Jun 24]. https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=IN. Accessed 30 Nov 2023."},{"key":"877_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/GO.20.00288","volume":"7","author":"N Gupta","year":"2021","unstructured":"Gupta N, Prinja S, Patil V, Bahuguna P. Cost-effectiveness of temozolamide for treatment of glioblastoma multiforme in India. JCO Glob Oncol. 2021;7:108\u201317.","journal-title":"JCO Glob Oncol."},{"key":"877_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12288-017-0843-7","volume":"34","author":"G Kaur","year":"2017","unstructured":"Kaur G, Prinja S, Malhotra P, Lad DP, Prakash G, Khadwal AR, Ramachandran R, Varma SC. Cost of treatment of multiple myeloma in a public sector tertiary care hospital of North India. Indian J Hematol Blood Transf. 2017;34:25\u201331.","journal-title":"Indian J Hematol Blood Transf"},{"key":"877_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43046-022-00123-6","volume":"34","author":"S Revannasiddaiah","year":"2022","unstructured":"Revannasiddaiah S, Nagaraju PRVMA, Palassery R, et al. The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis. J Egypt Natl Canc Inst. 2022;34:21. https:\/\/doi.org\/10.1186\/s43046-022-00123-6.","journal-title":"J Egypt Natl Canc Inst"},{"key":"877_CR43","doi-asserted-by":"publisher","first-page":"106167","DOI":"10.1016\/j.leukres.2019.106167","volume":"83","author":"CK Nair","year":"2019","unstructured":"Nair CK, Selvaraj K, Raghavan V, Manuprasad A, Shenoy PK, Kurup AR, et al. Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: lesson from a Tertiary Cancer Centre in rural India. Leuk Res. 2019;83:106167.","journal-title":"Leuk Res"},{"key":"877_CR44","first-page":"26","volume":"54","author":"TK Dolai","year":"2013","unstructured":"Dolai TK, Kumar M, Kumar Mandal P, Saha S, Bagchi B, Panigrahi A, et al. Auto-SCT for myeloma patients in non-HEPA filtered room: initial experience of a tertiary care center. Leuk Lymphoma. 2013;54:26.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"877_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/ijc.IJC_656_17","volume":"55","author":"N Khattry","year":"2018","unstructured":"Khattry N, Laskar S, Sengar M, Rangarajan V, Shet T, Subramanian PG, et al. Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian J Cancer. 2018;55(1):9-15. https:\/\/doi.org\/10.4103\/ijc.IJC_656_17.","journal-title":"Indian J Cancer"},{"issue":"21","key":"877_CR46","doi-asserted-by":"publisher","first-page":"01358","DOI":"10.1016\/j.jtct.2021.10.022","volume":"S2666\u20136367","author":"S Sidana","year":"2021","unstructured":"Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, et al. Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation. Transplant Cell Ther. 2021;S2666\u20136367(21):01358. https:\/\/doi.org\/10.1016\/j.jtct.2021.10.022.","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"877_CR47","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403.","journal-title":"Eur J Cancer"},{"issue":"1","key":"877_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/10428190309178811","volume":"44","author":"CT Kouroukis","year":"2003","unstructured":"Kouroukis CT, O\u2019Brien BJ, Benger A, Marcellus D, Foley R, Garner J, et al. Cost-efectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma. 2003;44(1):29\u201337.","journal-title":"Leuk Lymphoma"},{"key":"877_CR49","unstructured":"About Pradhan Mantri Jan Arogya Yojana (PM-JAY)|Official Website Ayushman Bharat Pradhan Mantri Jan Arogya Yojana|National Health Authority [Internet]. [cited 2021 Aug 20]. https:\/\/pmjay.gov.in\/about\/pmjay. Accessed 30 Nov 2023."},{"issue":"8","key":"877_CR50","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/heapol\/czu106","volume":"30","author":"W Dukpa","year":"2015","unstructured":"Dukpa W, Teerawattananon Y, Rattanavipapong W, Srinonprasert V, Tongsri W, Kingkaew P, et al. Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable disease interventions in Bhutan. Health Policy Plan. 2015;30(8):1032\u201343.","journal-title":"Health Policy Plan"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00877-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:19:28Z","timestamp":1718356768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00877-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00877-1","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"20 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by the Department of Health Research, Ministry of Health and Family Welfare, Government of India vide grant number F.No.T.11011\/02\/2017-HR\/3100291. However, the funder did not play a role in the design of the study; the collection, analysis and interpretation of the data; writing of the manuscript; and the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funder"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Conceptualization: SP, PM, JD. Data curation: SP, JD, PM. Formal analysis: JD, SP, PM. Funding acquisition: SP. Investigation: SP, PM, JD. Methodology: SP, JD, PM. Project administration: SP, JD. Resources: SP. Software: SP, JD. Supervision: SP, PM. Validation: SP, PM, JD, NM, AM, LK, AS, NG, MNK, PSR, ACK, SG. Visualization: SP, PM, JD, NM, AM, LK, AS, NG, MNK, PSR, ACK, SG. Writing\u2014original draft: JD, SP. Writing\u2014review and editing: SP, JD, PM, NM, AM, LK, AS, NG, MNK, PSR, ACK, SG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Ethical approval was obtained from the Institutional Ethics Committee of Post Graduate Institute of Medical Education and Research, India with reference number IEC-03\/20202-1565.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants for eliciting information on QoL and out-of-pocket expenditures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study participants consented to their data being used for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data underlying this article are available in the article and in its Online Supplementary Material. The datasets and analysis will be available upon request. The study investigators retain ownership of their data. Any requests for access to data should be made directly to study investigator.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The code that supports the findings of this study is available from the corresponding author on request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}